WorldCat Identities

Deutsch, Eric

Overview
Works: 38 works in 43 publications in 2 languages and 234 library holdings
Roles: Author, Opponent, Other, Thesis advisor
Classifications: TS157.5, 616.994
Publication Timeline
.
Most widely held works by Eric Deutsch
Master planning and scheduling : an essential guide to competitive manufacturing by Eric Deutsch( )

5 editions published between 2021 and 2022 in English and Undetermined and held by 185 WorldCat member libraries worldwide

Discover the practical, real-world advantages of the Oliver Wight master planning and scheduling methodology. The newly revised Fourth Edition of Master Planning and Scheduling: An Essential Guide to Competitive Manufacturing delivers a masterful exploration of today's master planning and scheduling techniques, as well as an insightful discussion of the future of the master planning and scheduling processes and profession. Written in the context of an ever-evolving digital environment and augmented with new and critical information required to implement best practices, the book is a guide for practitioners and leaders on the principles of master planning and scheduling and its application in modern and future work environments. In this book, readers will learn: Insights regarding top-down, bottom-up, and side-to-side integration of business practices in support of a company's strategic direction and tactical deployment The critical link between time-phased integrated business planning, master planning, master scheduling, capacity planning, and material planning "How-to" details and examples to support master planning and scheduling implementation and enhancements within the company's demand and supply organizations Master Planning and Scheduling is an indispensable guide for supply chain professionals, planners and schedulers in all functional domains of a business. It also belongs on the bookshelves of any executive or manager who seeks to improve their understanding of best practice planning and scheduling processes and how those processes enable a business to outperform the competition through alignment, integration and synchronization across all functions in an organization
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors by Rastislav Bahleda( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors by Romain-David Seban( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics by Romain-David Seban( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Traitement des métastases cérébrales par radiothérapie et nanoparticule de gadolinium : du modèle pré clinique à l'utilisation chez l'homme by Camille Verry( )

1 edition published in 2018 in French and held by 2 WorldCat member libraries worldwide

L'apparition de métastases cérébrales multiples est une évolution critique de nombreux cancers avec un impact majeur sur la survie globale. Une nouvelle nanoparticule à base de gadolinium, l'AGuIX®, a récemment démontré son efficacité en tant que radiosensibilisant et agent de contraste IRM dans plusieurs études précliniques. L'objectif de cette thèse est d'établir une preuve de concept sur un modèle animal puis de réaliser la première administration chez l'homme de ce nouveau médicament dans le cadre d'un essai de phase 1.La première partie de ce travail a consisté à l'irradiation en 6 MeV après injection d'AGuIX® d'un modèle de rat Fisher porteur du gliome cérébral 9L suivi par IRM. Nous avons mis en évidence une distribution favorable des nanoparticules dans la tumeur par effet EPR (Enhanced Permeability and Retention) avec une concentration de gadolinium dans la tumeur 20 fois plus importante que dans le cerveau sain. L'effet radiosensibilisant a été démontré avec une diminution significative (p=0.02) de la taille des tumeurs dans le groupe irradié après injection d'AGuIX®. Ces résultats, associés au profil de tolérance favorable sur les modèles animaux ont motivés le transfert chez l'homme de ce nouveau médicament dans une étude de phase 1 nommée NANO-RAD (EudraCT 2015-004259-30 ; NCT02820454). Il s'agit d'une étude monocentrique, ouverte, évaluant la faisabilité et la tolérance d'AGuIX® associé à une irradiation panencéphalique (30 Gy, 10 Fr de 3 Gy) pour des patients atteints de métastases cérébrales multiples. L'objectif principal est de déterminer la dose maximale tolérée des nanoparticules avec un schéma d'escalade de dose par palier de 3 patients à 15, 30, 50, 75 et 100 mg/kg. Les objectifs secondaires sont l'étude pharmacocinétique de la distribution d'AGuIX® par IRM, de la survie sans progression intracrânienne et de la survie globale. La première administration chez l'homme a été réalisée au CHU de Grenoble le 18 juillet 2016 et le dernier patient (n=15) a été inclus le 06 février 2018. L'ensemble des lésions, quelques soit l'origine histologique (poumon, mélanome, sein) ont eu une prise de contraste d'AGuIX® dont la concentration retrouvée dans la tumeur était proportionnelle à la dose injectée. La demi-vie sanguine moyenne est de 1h09 (± 26min). La tolérance au traitement a été bonne avec une escalade de dose jusqu'à 100 mg/kg qui devient ainsi la dose retenue pour la suite des essais cliniques. Sur les 14 patients évaluables, 12 ont eu un bénéfice clinique du traitement avec une diminution du volume tumoral. Les résultats préliminaires sont prometteurs en termes de tolérance, de distribution et d'efficacité et devront être confirmés par l'étude de phase 2 multicentrique randomisée prévue pour la fin de l'année 2018
Anti-PD-1 Vasculitis of the central nervous system or radionecrosis? by Roger Sun( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer by Antoine Schernberg( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Caractérisation et modulation des évènements initiaux contrôlant la mort radioinduite de l'endothélium microvasculaire by Colin Niaudet( )

2 editions published between 2009 and 2021 in French and held by 2 WorldCat member libraries worldwide

Une irradiation unique à forte dose déclenche l'apoptose du compartiment microvasculaire via le couple sphingomyélinase acide/céramide, contrôlant l'ensemble du processus de destruction tissulaire. Nous avons étudié la connexion entre cette apoptose contrôlée par l'ASMase et la capacité largement démontrée du céramide à induire la coalescence des microdomaines membranaires en larges plateformes. L'irradiation induit simultanément la voie de mort p38, dont l'inhibition protège partiellement les cellules endothéliales de la mort radioinduite. Enfin, la désorganisation des rafts par un agent dépléteur du cholestérol entrave l'activation de p38 et la mort des cellules microvasculaires qui en résulte. Ces résultats suggèrent l'existence d'un mécanisme de mort émanant de la membrane spécifique aux cellules endothéliales irradiées, dans lequel la coalescence des rafts mène à l'activation de la voie de mort p38. Nous avons ensuite utilisé la sphingosine-1-phosphate (S1P), un antagoniste du céramide, pour moduler cette vague précoce de mort radioinduite dans l'endothélium. Nous avons validé l'usage de la S1P comme agent systémique capable de limiter les défaillances aigues survenant dans les organes suite à l'exposition à des stress sévères : l'injection de S1P abolit l'effondrement de l'endothélium et ainsi empêche la survenue du syndrome gastro-intestinal à 15 Gy, tout comme le choc septique induit par le LPS, un autre syndrome contrôlé par l'apoptose microvasculaire. Cette protection exercée par la S1P sur l'endothélium présente une double spécificité : les sphingolipides apparentés sont incapables d'induire un niveau de protection équivalent de l'endothélium, et l'effet pro-survie de la S1P est dirigé uniquement vers l'endothélium et non vers les cellules épithéliales intestinales ou les lymphocytes. L'effet protecteur de la S1P est médié par les récepteurs couplés aux protéines G, puis les protéines pro-survie Akt, comme le prouvent l'inhibition de ces deux types de molécules qui, in vivo comme in vitro, supprime l'action de la S1P
Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death by Isabelle Martins( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? by Barouyr Baroudjian( )

1 edition published in 2014 in English and held by 2 WorldCat member libraries worldwide

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours by Vincent A de Weger( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models by Céline Clémenson( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Development and Mechanism of Action of the DNA Repair Inhibitor AsiDNA in the Treatment of Medulloblastoma with Radiotherapy by Sofia Ferreira( )

1 edition published in 2019 in English and held by 1 WorldCat member library worldwide

Medulloblastoma is the most common central nervous system malignancy in pediatric oncology. Despite good overall survival rates, medulloblastoma treatment plans face two major clinical problems: survivors of medulloblastoma often present severe and irreversible sequela caused by the treatments and, certain subgroups of the disease will respond poorly to the treatments. In this work we aimed at tackling both clinical issues by improving radiotherapy efficacy in medulloblastoma preclinical models using a DNA repair inhibitor in clinical trials, AsiDNA. We have characterized the effect of AsiDNA in combination with radiation in vitro and in vivo studies. We have observed that AsiDNA can penetrate young brains and brain tumors through systemic delivery. No evidences of additional radiation-associated brain toxicity were observed. In addition, combination of AsiDNA treatments to lethal doses of radiation delivered in developing murine brain seem to protect from the radiation-induced toxicity. Our results show that the combination of AsiDNA to radiation improves survival of subcutaneous and orthotopic models of medulloblastoma. Transcriptome analysis on medulloblastoma cell lines indicate that AsiDNA intensifies the transcriptional response to radiation resembling the increase in radiation doses. This effect is independent of the cell of origin or TP53 status of the cells. The obtained results indicate that AsiDNA may be a good candidate to improve the efficacy of treatment protocols and quality of life of medulloblastoma patients
Au-delà de la mesure de SUV en imagerie TEP : propriétés et potentiel des paramètres de texture pour caractériser les tumeurs by Fanny Orlhac( )

1 edition published in 2015 in French and held by 1 WorldCat member library worldwide

The precise characterization of the biological heterogeneity of a tumor is a major issue in oncology. The calculation of biomarkers reflecting this heterogeneity directly from imaging data offers a number of advantages: it is non-invasive, can be repeated during the therapy, does not require supplementary examinations and the whole tumor and possible metastases can be investigated from the images. My research project was to develop and assess methods to characterize the metabolic activity distribution in tumors.Texture analysis based on PET images requires a protocol to compute index that is somehow more sophisticate than when simply measuring the conventional index used in clinical practice. To determine the role of the different steps that are involved in the computation of texture index, a methodological study was conducted. This study demonstrated that some texture parameters were redundant and that there existed a strong correlation between some of them and the metabolic volume. We have also shown that the formula and the rate of discretization impact the texture analysis and clarified the interpretation of these metrics. After the protocol of texture index computation has been established, the second part of this work was to assess the interest of these indices for the tumor characterization. We showed that some texture indices were different in tumor and in healthy tissue and could identify histological types such as the triple-negative breast tumors, the squamous cell carcinoma from adenocarcinoma in lung tumors, as well as the grade of gliomas.To understand the links between the tumor heterogeneity as measured from PET images and the biological heterogeneity of lesions, we compared the texture analysis based on different scales in a mouse model. This study revealed that the texture measured in vivo based on PET images reflects the texture measured ex vivo from autoradiographic images
Extraction et analyse de biomarqueurs issus des imageries TEP et IRM pour l'amélioration de la planification de traitement en radiothérapie by Sylvain Reuzé( )

1 edition published in 2018 in French and held by 1 WorldCat member library worldwide

Beyond the conventional techniques of diagnosis and follow-up of cancer, radiomic analysis allows to personalize radiotherapy treatments, by proposing a non-invasive characterization of tumor heterogeneity. Based on the extraction of advanced quantitative parameters (histograms of intensities, texture, shape) from multimodal imaging, this technique has notably proved its interest in determining predictive signatures of treatment response. During this thesis, signatures of cervical cancer recurrence have been developed, based on radiomic analysis alone or in combination with conventional biomarkers, providing major perspectives in the stratification of patients that can lead to dosimetric treatment plan adaptation.However, various methodological barriers were raised, notably related to the great variability of the protocols and technologies of image acquisition, which leads to major biases in multicentric radiomic studies. These biases were assessed using phantom acquisitions and multicenter patient images for PET imaging, and two methods enabling a correction of the stratification effect were proposed. In MRI, a method of standardization of images by harmonization of histograms has been evaluated in brain tumors.To go further in the characterization of intra-tumor heterogeneity and to allow the implementation of a personalized radiotherapy, a method for local texture analysis has been developed. Specifically adapted to brain MRI, its ability to differentiate sub-regions of radionecrosis or tumor recurrence was evaluated. For this purpose, parametric heterogeneity maps have been proposed to experts as additional MRI sequences.In the future, validation of the predictive models in external centers, as well as the establishment of clinical trials integrating these methods to personalize radiotherapy treatments, will be mandatory steps for the integration of radiomic in the clinical routine
Evaluation préclinique de trois nouvelles stratégies de radiosensibilisation pharmacologique : modulation de p53/Mdm2, perturbation de la dynamique des microtubules et ciblage de MET/Aurora B by Cyrus Chargari( )

1 edition published in 2014 in French and held by 1 WorldCat member library worldwide

Les résultats insuffisants de la radiochimiothérapie conventionnelle ont motivé l'évaluation de nouvelles cibles afin de moduler la radiosensibilité tumorale: voies intrinsèques impliquées dans la réponse aux rayonnements ionisants, vascularisation tumorale, stroma non vasculaire. A travers cette thèse, nous avons évalué trois nouvelles stratégies de radiosensibilisation pharmacologique. Nous avons d'abord étudié en association à la radiothérapie l'intérêt de la modulation de l'axe p53/Mdm2 par le JNJ26854165, un inhibiteur de la dégradation de p53 par le protéasome. Les résultats in vitro et in vivo dans des xénogreffes sous-cutanées de cancers bronchiques non à petites cellules (CBNPC) montrent que cette stratégie permet d'améliorer significativement l'efficacité de la radiothérapie. Nous avons également rapporté des résultats encourageants in vitro dans plusieurs lignées cellulaires tumorales avec un nouvel agent antivasculaire ciblant la tubuline, l'EHT 6706. Cette stratégie augmentait l'efficacité de l'irradiation et potentialisait l'effet antiprolifératif de certains agents de chimiothérapie conventionnelle. Enfin, le développement le plus abouti a consisté en l'évaluation de l'association d'un triple inhibiteur de MET/AXL/FGFR en association à l'irradiation in vitro et dans des modèles de CBNPC implantés en xénogreffes sous-cutanées, mais également sous forme de tumeurs pulmonaires orthotopiques. Cet agent pharmacologique potentialisait l'efficacité de la radiothérapie dans des lignées ne surexprimant pas MET. Il est apparu que l'activité de la drogue faisait intervenir, au moins partiellement, l'inhibition de l'activité d'acteurs de la cytocinèse. Ces trois évaluations, qui s'inscrivent dans la recherche translationnelle, montrent l'importance de la recherche préclinique pour les études d'association aux rayonnements ionisants. Seul un développement préclinique rationnel permettra de faire émerger de nouveaux standards dans le domaine de la biomodulation pharmacologique de la radiosensibilité tumorale
Characterization of the Signaling Pathways Involved in Cellular Cannibalism Elicited by Ionizing Radiation by Dorine De Jong( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Many types of anticancer therapies are available to kill tumor cells. The tumoral cell death modalities may be different upon the treatment, the cell type and inter-individual sensitivity. Besides the typical cell death processes apoptosis and necrosis, cellular cannibalism has also been reported in patients' tumoral biopsies. This cellular process is defined as the engulfment of one live cell by another live cell followed by the degradation of the inner cell. The mechanisms beyond cellular cannibalism are still partially understoof but it appears to be of clinical relevance. Indeed, we have shown that these events could be modulated by anticancer treatments and there are evidences of their utility as a potent prognostic biomarker in some cancers. This thesis presents the in vitro experiments which led to the identification of the signaling pathways involved in cellular cannibalism induced by ionizing radiation
Study of Interaction Between the Inflammatory Response and Radiation-Induced Fibrosis by Lydia Meziani( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Libération extra-cellulaire de microARN et de complexes nucléo-protéiques par les cellules infectées par EBV : rôle des exosomes et d'autres transporteurs by Claire Gourzones( )

1 edition published in 2011 in French and held by 1 WorldCat member library worldwide

The study of tumoral microenvironment should take into account different modes of intercellular communications: direct contacts between extracellular membranes, secretion and uptake of cytokines and finally emission and uptake of complex biological objects like exosomes and microvesicles.Epstein-Barr virus (EBV) is associated with several human malignancies of epithelial origin (Nasopharyngeal carcinoma or NPC) or of lymphoïd origin (post-transplant lymphoproliferative disorder or PTLD). In these tumors, malignant cells are latently infected by EBV and release exosomes and microvesicles containing viral nucleic acids and proteins. Studying them will enable a better understanding of tumor-host interactions and the discovery of new markers which could be useful for early diagnostic and the follow-up of the disease under treatment.The first aim of this thesis was to study the release by malignant cells of EBV microRNAs belonging to the BART family and their blood diffusion in patients bearing NPC tumors. For the first time, I've shown that exosomes released by NPC cells in vitro contain EBV miR-BART microRNAs. Moreover, ebv-miR-BART7 can be detected in the plasma of NPC patients. Unlike what is observed in vitro, circulating BART microRNAs are not carried by exosomes. Recent data from studies in xenografted mice show that they are carried by extra-cellular complexes which can be immunoprecipitated by anti-Ago2 antibodies. We are currently trying to confirm these data in plasma from NPC patients. This work will ease the use of miR-BARTs as potential biomarkers.The second aim was to study the proteome modifications induced by the EBV Latent Membrane Protein 1 protein (LMP1). I've shown that LMP1 expression in lymphoid or epithelial cells infected or not by EBV induces the release of PARP1 in the extra-cellular space. This extra-cellular PARP1 is not carried by exosomes or microvesicles but is embedded in non-vesicular nano-objects containing histones and DNA. We have called these objects “DNA-proteins complexes”. We don't know how they are produced and released by cells. We think that they are not only secreted by apoptotic cells. Recent data show that this release of extra-cellular PARP1 is associated with PARP1 activation by LMP1 oncoprotein expression. We are trying to prove this hypothesis using cell lines expressing wild type or mutated LMP1. The release and the activation of PARP1 induced by LMP1 expression will help to understand the mechanisms of EBV-associated oncogenesis and auto-immunity
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.00 (from 0.00 for Master pla ... to 0.00 for Master pla ...)

Master planning and scheduling : an essential guide to competitive manufacturing
Covers
Alternative Names
Eric Deutsch wetenschapper

Languages
English (17)

French (7)